Vaccine Upstart Inviragen Aims to Capture Dengue Market
Executive Summary
Six-year-old Inviragen may be the biotech of the future.
You may also be interested in...
Vaccine Funding And Access Key To Pharma Success In Developing World
Vaccine consultant Jacqueline Keith in an interview described promising advances but also challenges to the funding, development, and delivery of vaccines to the neediest populations. The role of public/private partnerships at each stage of the vaccine value chain is critical to assuring win-win outcomes.
Sanofi Dengue Vaccine Suffers Mixed Trial Results, But High Unmet Need Could Help It Forward
The efficacy seen in Sanofi’s Phase IIb dengue vaccine trial was modest. At least one dengue vaccine expert thinks the pharma would stand a better chance if it developed the vaccine as one dose instead of three.
Sanofi Dengue Vaccine Suffers Mixed Trial Results, But High Unmet Need Could Help It Forward
The efficacy seen in Sanofi’s Phase IIb dengue vaccine trial was modest. At least one dengue vaccine expert thinks the pharma would stand a better chance if it developed the vaccine as one dose instead of three.